Adagene Inc. has announced a strategic partnership with ConjugateBio Inc. to advance the development of novel antibody drug conjugates (ADCs). As part of the agreement, Adagene will supply a proprietary antibody for ConjugateBio's bispecific ADC programs. In return, Adagene will receive an undisclosed upfront payment, along with milestone and royalty payments, while retaining all non-ADC rights to the antibody. This collaboration aims to leverage Adagene's distinguished antibody discovery capabilities and ConjugateBio's expertise in ADC development, potentially expanding the ADC market, which is projected to exceed $30 billion by 2030.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.